ClinicalTrials.gg
Enrolling by invitationNCT05185505Updated Oct 8, 2026

Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria

A Phase 4 interventional study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Hepatocellular Cancer, sponsored by The Methodist Hospital Research Institute. Enrolling by invitation at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by The Methodist Hospital Research Institute · Phase 4, Interventional, and Treatment

How we know · 5 judgments

Updated Oct 8, 2026Now Enrolling by invitationFirst site in Canada+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies testing atezolizumab in Carcinoma, Hepatocellular — 17 open to participants now, 29 under way, 7 of them phase 3. atezolizumab · Carcinoma, Hepatocellular.

Planned enrollment
31st of 41
24 · median 40
Started
2023
with 5 others
Phase 4
2 of 41
2 open now
Primary completion
2027-04
later than 14 of 28 live
Registered
20th of 41
by date

Among the 41 studies testing atezolizumab in Carcinoma, Hepatocellular, this one is the 31st largest by planned enrollment, is one of 6 that started in 2023, is one of 2 in phase 4, reaches primary completion later than 14 of the 28 other live ones, and was the 20th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

17 of the 41 studies testing atezolizumab in Carcinoma, Hepatocellular are open now, in 11 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About atezolizumab

atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing atezolizumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

Patients with hepatocellular carcinoma (HCC) beyond Milan Criteria (MC) who are undergoing evaluation for or waitlisted for liver transplantation will be treated with 6 months of neoadjuvant/downstaging atezolizumab plus bevacizumab while receiving standard of care transarterial chemoembolization (TACE) or transarterial radioembolization (TARE). We hypothesize that atezolizumab and bevacizumab can appropriately bridge patients with HCC beyond MC to transplantation and not increase the risk of 1-year post-transplant rejection.

Read the detailed description

Hepatocellular carcinoma (HCC) represents the second most common cause of cancer-related death and accounts for over 80% of primary liver cancers worldwide. Curative treatment options include surgical resection in patients with well compensated liver function and radio frequency ablation in small tumors. However, in 90% of patients, HCC occurs in the setting of cirrhosis where optimal management remains liver transplantation (LT) with 5-year survival rates of approximately 80%. Despite the success of LT in treating HCC, only a small portion of patients fit into standard Milan Criteria to receive a LT due to 1) advanced-stage disease and/or large tumor size preventing/delaying organ allocation and 2) a lack of neoadjuvant (bridging) therapies that can effectively down-stage or delay tumor progression for patients while on the LT waiting list. The proposed clinical trial will evaluate the feasibility of using a combination of the chemotherapeutic interventions atezolizumab and bevacizumab in a group of patients with HCC who have tumors beyond the Milan Criteria (in brief, 5 - 10 cm), in order to appropriately bridge them to liver transplantation without increasing the risk of graft rejection within 1-year post-LT.

03

Conditions studied

  • Hepatocellular Carcinoma
  • Hepatocellular Cancer

Keywords

  • Bevacizumab
  • atezolizumab
  • Neoadjuvant Therapy
  • Liver Neoplasms
  • Liver Transplantation
04

Who can participate

The criteria were revised on the registry on Oct 8, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged ≥18 years old at the time of signing Form
  2. Measurable or evaluable disease per v1.1 or of unresectable HCC outside of Milan criteria
  3. Histologically or radiologically proven HCC, without extrahepatic disease. Patients who consent to a fresh tissue biospy, and under the discretion of the Investigators, will provide a baseline sample for diagnosis and correlative studies. Archival tumor tissue may be used to confirm HCC in patients who do not consent to a fresh tissue biopsy.
  4. Prior remote LRT is allowed if new lesions or local disease recurrence are present. Participants may have received one TACE or TARE treatment within 8 weeks prior to enrollment, whether or not new lesions are present.
  5. Must be undergoing evaluation for or waitlisted for liver transplantation
  6. Eligible and suited to receive TACE or TARE procedure(s)
  7. score ≤B7
  8. (ECOG) score 0-1
  9. of ≥ 6 months
  10. Adequate hematological and end-organ function, defined by the following laboratory test results obtained within 14 days prior to study initiation:

    1. (ANC) ≥ 1.5 x 109/L
    2. Lymphocyte count ≥ 0.5 x 10\^9/L (500/μL)
    3. count > 75 x 10\^9/L
    4. ≥ 9 g/dL
    5. Total \< 1.5 x (ULN)
    6. (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) \< 2.5 x ULN
    7. Serum albumin > 2.7 g/dL
    8. Serum creatinine \< 1.5x ULN
    9. Urine dipstick for proteinuria ≤ 2+ unless a 24-hour urine protein \< 1 g of protein is demonstrated
    10. (INR) ≤ 1.5 or partial thromboplastin time (PTT) ≤ 1.5 x ULN for patients not receiving anti-coagulation. The use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or PTT is within therapeutic limits (according to the medical standard of the enrolling institution) and the patient has been on a stable dose of anticoagulants for at least two weeks prior to the first study treatment.
  11. No history of hemoptysis (≥ 1/2 teaspoon of bright red blood per episode) within 1 month of study enrollment
  12. Negative test at screening or transplant workup
  13. Documentation of referral to the Transplant Hepatology team for appropriate evaluation and management of patients who have one or more of the following:

    • Positive surface antigen (HBsAg) test at screening
    • Positive total hepatitis B core antibody (HBcAb) test at screening followed by a positive hepatitis B virus (HBV) DNA test at screening. The HBV DNA test must be performed only for patients who have a negative HBsAg test and a positive total HBcAb test.
    • Positive virus (HCV) antibody test at screening followed by a positive HCV RNA test at screening. The HCV RNA test must be performed for patients who have a positive HCV antibody test.
  14. For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use methods, as defined below:

    1. Women must remain abstinent or use contraceptive methods with a failure rate of \<1% per year during the treatment period and for 6 months after the final dose of atezolizumab/bevacizumab Females who receive a LT are required to maintain abstinence or contraception until the End of Study.
    2. A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a state (≥12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). The definition of childbearing potential may be adapted for alignment with local guidelines or requirements.
    3. Examples of contraceptive methods with a failure rate of \<1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.
    4. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (eg, calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception.
  15. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below:

    1. With a female partner of childbearing potential or pregnant female partner, men must remain abstinent or use a condom during the treatment period and for 6 months after the final dose of atezolizumab/bevacizumab to avoid exposing the embryo. Men must refrain from donating sperm during this same period. Males who receive a LT are required to maintain these criteria until the End of Study.
    2. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (eg, calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of preventing drug exposure.
  16. Stated willingness to comply with all study procedures and availability for the duration of the study
  17. Women of childbearing potential must have a negative serum or urine pregnancy test result within 14 days prior to initiation of study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Known fibrolamellar HCC, sacromatoid HCC, or mixed cholangiocarcinoma and HCC
  2. Previous systemic therapy for HCC prior to study enrollment
  3. Planned or prior multi-organ transplant or prior solid organ or stem cell transplantation
  4. History of Grade ≥4 venous thromboembolism
  5. History or evidence upon physical or neurological examination of central nervous system (eg seizures) unrelated to cancer unless adequately treated with standard medical therapy. Anticonvulsants (stable dose) are allowed.
  6. Moderate or severe ascites
  7. History of hepatic encephalopathy
  8. Inadequately controlled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg)
  9. History of hypertensive crisis or hypertensive encephalopathy
  10. Evidence of a Grade 2 or higher esophageal and/or gastric varices. Patients must have an esophagogastroduodenoscopy (EGD) within 6 months prior to initiating the study treatment. See Section 8.7.1.2. If the EGD shows Grade 2 or higher esophageal and/or gastric varices, patients will be excluded and will not receive study treatment but can be re-evaluated for enrollment after successful treatment of varices according to institutional guidelines.
  11. Significant vascular disease (eg, aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to drug administration
  12. cardiovascular disease, such as cerebrovascular accidents within 12 months prior to randomization, myocardial infarction within 12 months prior to randomization, unstable angina, (NYHA) Grade II or greater CHF, or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with study treatment
  13. History or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (ie, in the absence of therapeutic anticoagulation)
  14. Major surgical procedure (including open , surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to initiation of study treatment, or anticipation of need for major surgical procedure during the Treatment Phase of the study

    • Treatment should not be initiated within 7 days of having a core biopsy or other minor surgical procedure.
    • Treatment should not be initiated within 2 days of placement of a vascular access device.
  15. History of abdominal fistula, gastrointestinal (GI) perforation, intra-abdominal abscess, grade 2 or higher untreated esophageal or gastric varices or active GI bleeding within 6 months prior to treatment
  16. Serious, non-healing wound, active ulcer, or untreated bone fracture
  17. Other within 5 years prior to randomization, except for localized cancer in situ, such as basal or squamous cell skin cancer
  18. Current or recent (\<10 days prior to initiation of study treatment) use of aspirin (>325 mg/day), or clopidogrel (>75 mg/day). Note: The use of full-dose oral or parenteral anticoagulants for therapeutic purpose is permitted as long as the and/or a PTT is within therapeutic limits (according to institution standards) within 7 days prior to initiation of study treatment and the patient has been on a stable dose of anticoagulants for ≥2 weeks prior to initiation of study treatment. Prophylactic use of anticoagulants is allowed. However, the use of direct oral anticoagulant therapies such as apixaban (Eliquis®), dabigatran (Pradaxa®), and rivaroxaban (Xarelto®) is not recommended due to bleeding risk, unless approved by the treating physician and the primary investigator.
  19. Pregnancy (positive pregnancy test) or lactation, or intention of becoming pregnant during study treatment or within 6 months after the final dose of study drugs

    • Women of must have a negative serum or urine pregnancy test result within 28 days prior to initiation of study treatment.
  20. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)

    • Patients with indwelling catheters (eg, PleurX®) are allowed
  21. Uncontrolled or symptomatic hypercalcemia (ionized calcium >1.5 mmol/L, calcium >12 mg/dL or corrected serum calcium >)
  22. Active or history of disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis, with the following exceptions:

    • Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study.
    • Patients with controlled Type 1 Diabetes Mellitus who are on an insulin regimen are eligible for the study
    • Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (eg, patients with psoriatic arthritis are excluded) are eligible for the study provided all following conditions are met:

      • Rash must cover \<10% of body surface area
      • Disease is well controlled at baseline and requires only low-potency topical
      • No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months
  23. History of idiopathic pulmonary fibrosis, organizing pneumonia (eg, bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
  24. Active tuberculosis
  25. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications
  26. Treatment with a live, attenuated vaccine (eg, FluMist®) within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab
  27. Treatment with investigational therapy within 28 days prior to initiation of study treatment
  28. Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including , anti-PD-1, and anti-PD-L1 therapeutic antibodies
  29. Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 [IL-2]) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment
  30. Treatment with systemic medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-α agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the Treatment Phase, with the following exceptions:

    • Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (eg, 48 hours of corticosteroids for a contrast allergy) are eligible for the study after Principal Investigator confirmation has been obtained.
    • Patients who received mineralocorticoids (eg, fludrocortisone), corticosteroids for (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.
  31. History of severe allergic anaphylactic reactions to chimeric or humanized antibodies or fusion proteins
  32. Known allergy or to any component of the Atezlizumab and Bevacizumab formulation, such as a known hypersensitivity to Chinese hamster ovary cell products
  33. Inability to comply with study and/or follow-up procedures
  34. Active infection requiring IV antibiotics within 2 weeks prior to initiation.

    • Note: Placement of a vascular access device should be at least 2 days prior to initiation of study treatment.
    • Patients receiving prophylactic antibiotics (eg, to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.
  35. Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
  36. History of
  37. Evidence of abdominal free air that is not explained by paracentesis or recent surgical procedure
  38. History of intra-abdominal inflammatory process within 6 months prior to initiation of study treatment, including but not limited to active peptic ulcer disease, diverticulitis, or colitis.
  39. Chronic daily treatment with a nonsteroidal anti-inflammatory drug (NSAID). Occasional use of NSAIDs for the symptomatic relief of medical conditions such as headache or fever is allowed
  40. Uncontrolled tumor-related pain

    • Patients requiring pain medication must be on a stable regimen at study entry.
    • Symptomatic lesions (eg, bone or metastases causing nerve impingement) amenable to palliative radiotherapy should be treated prior to enrollment. Patients should be recovered from the effects of radiation. There is no required minimum recovery period.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Atezolizumab + Bevacizumab

    Patients will receive transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) approximately every 3 months, with a maximum of 4 treatments, plus atezolizumab combined with bevacizumab. Atezolizumab and bevacizumab will commence at least 3 weeks post the first TACE or TARE. Thereafter, patients will proceed to cycles 1-3 of atezolizumab/bevacizumab every 3 weeks.

    Drug: Atezolizumab · Drug: Bevacizumab

Interventions

  • 1200 mg administered every three weeks for up to 6 months (up to 8 cycles) during the liver transplant waiting period

    Also known as: Tecentriq

  • 15 mg/kg administered every three weeks for up to 6 months (up to 8 cycles) during the liver transplant waiting period

    Also known as: Avastin

06

What researchers measure

Primary outcomes

  1. Proportion of Patients Receiving Liver Transplant Experiencing Acute Rejection

    Whether the proportion of liver transplant patients who have acute allograft rejection is ≤30%

    Time frame: Within 1 year after liver transplant

Secondary outcomes

  1. Proportion of participants who experience treatment-emergent adverse events

    Number of patients who experience an FDA-defined adverse event due to the experimental treatment

    Time frame: Within 90 days of study drug administration

  2. Objective Response Rate

    Combined incidence of partial response and complete response of tumors to therapy determined using modified RECIST (mRECIST) and RECIST 1.1 criteria, defined as combined incidence of partial and complete response

    Time frame: 6 months post study drug initiation

  3. Proportion of participants who are removed from the liver transplant waiting list after initiating the atezolizumab/bevacizumab therapy

    Number of participants who had been on the liver transplant waitlist but are removed

    Time frame: Through study completion, up to 4 years

  4. The proportion of participants who proceed to liver transplantation

    Participants who receive a liver transplant

    Time frame: Through study completion, up to 4 years

  5. Proportion of the liver explant tissue containing necrotic tumors

    Number of livers explanted during liver transplant that are found to contain necrotic tumors via pathology

    Time frame: Through study completion, up to 4 years

  6. Recurrence-free survival in patients receiving a liver transplant

    Measure of how many patients experience hepatocellular carcinoma recurrence

    Time frame: Within 1 year after liver transplant

  7. Overall survival after liver transplant

    Number of patients who are still alive after receiving a liver transplant (taking into account death of any cause)

    Time frame: Study enrollment to 1 year after liver transplant, time of liver transplant to 1 year after liver transplant

  8. Overall Survival after Study Enrollment

    Number of patients who are still alive after enrolling in the study (taking into account death of any cause)

    Time frame: Through study completion, up to 4 years

  9. Tumor biomarkers

    Measurement of alpha fetoprotein tumor biomarker from blood samples

    Time frame: At enrollment; at time of first dose of atezolizumab/bevacizumab; 3, 6, 9, 12, 15, 18, 21, 24, 30, 39 weeks after first dose; at time of liver transplant; 1, 6, and 12 months after liver transplant

  10. Immune Cell Biomarkers

    Measurement of biomarkers in immune cells gathered via blood samples: 1) PD-L1+ in CD4+ and CD8+ cells and 2) FOXP3, CD127, and IL-8 in T regulatory cells

    Time frame: At enrollment; at time of first dose of atezolizumab/bevacizumab; 3, 6, 9, 12, 15, 18, 21, 24, 30, 39 weeks after first dose; at time of liver transplant; 1, 6, and 12 months after liver transplant

07

Study locations

2 sites
08

References and documents

Publications

  • Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. PubMed 21296855 ↗
  • Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010 Jul;42 Suppl 3(Suppl 3):S206-14. doi: 10.1016/S1590-8658(10)60507-5. PubMed 20547305 ↗
  • Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017 Apr;14(4):203-217. doi: 10.1038/nrgastro.2016.193. Epub 2017 Jan 5. PubMed 28053342 ↗
  • Tecentriq [Package Insert]. South San Francisco, CA: Genentech, Inc.; 2020.
  • Avastin [Package Insert]. South San Francisco, CA: Genentech, Inc.; 2020.
  • Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996 Mar 14;334(11):693-9. doi: 10.1056/NEJM199603143341104. PubMed 8594428 ↗
  • Sapisochin G, Goldaracena N, Laurence JM, Dib M, Barbas A, Ghanekar A, Cleary SP, Lilly L, Cattral MS, Marquez M, Selzner M, Renner E, Selzner N, McGilvray ID, Greig PD, Grant DR. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology. 2016 Dec;64(6):2077-2088. doi: 10.1002/hep.28643. Epub 2016 Jun 30. PubMed 27178646 ↗
  • O'Rourke JM, Shetty S, Shah T, Perera MTPR. Liver transplantation for hepatocellular carcinoma: pushing the boundaries. Transl Gastroenterol Hepatol. 2019 Jan 2;4:1. doi: 10.21037/tgh.2018.12.07. eCollection 2019. No abstract available. PubMed 30854488 ↗
  • Gorgen A, Rosales R, Sadler E, Beecroft R, Knox J, Dawson LA, Ghanekar A, Grant D, Greig PD, Sapisochin G. Patterns and Predictors of Mortality After Waitlist Dropout of Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. Transplantation. 2019 Oct;103(10):2136-2143. doi: 10.1097/TP.0000000000002616. PubMed 30801510 ↗
  • Finn RS, Qin S, Ikeda M, et al. Imbrave150: Updated Overall Survival (Os) Data from a Global, Randomized, Open-Label Phase Iii Study of Atezolizumab (Atezo) + Bevacizumab (Bev) Versus Sorafenib (Sor) in Patients (Pts) with Unresectable Hepatocellular Carcinoma (Hcc). Journal of Clinical Oncology. 2021;39(3_suppl):267-267.
  • Opdivo [Package Insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2018.
  • Schwacha-Eipper B, Minciuna I, Banz V, Dufour JF. Immunotherapy as a Downstaging Therapy for Liver Transplantation. Hepatology. 2020 Oct;72(4):1488-1490. doi: 10.1002/hep.31234. No abstract available. PubMed 32171041 ↗
  • Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, Srinivas S, Retz MM, Grivas P, Joseph RW, Galsky MD, Fleming MT, Petrylak DP, Perez-Gracia JL, Burris HA, Castellano D, Canil C, Bellmunt J, Bajorin D, Nickles D, Bourgon R, Frampton GM, Cui N, Mariathasan S, Abidoye O, Fine GD, Dreicer R. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 7;387(10031):1909-20. doi: 10.1016/S0140-6736(16)00561-4. Epub 2016 Mar 4. PubMed 26952546 ↗
  • Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D, Artal-Cortes A, Lewanski C, Braiteh F, Waterkamp D, He P, Zou W, Chen DS, Yi J, Sandler A, Rittmeyer A; POPLAR Study Group. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016 Apr 30;387(10030):1837-46. doi: 10.1016/S0140-6736(16)00587-0. Epub 2016 Mar 10. PubMed 26970723 ↗
  • Lee MS, Ryoo BY, Hsu CH, Numata K, Stein S, Verret W, Hack SP, Spahn J, Liu B, Abdullah H, Wang Y, He AR, Lee KH; GO30140 investigators. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020 Jun;21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X. PubMed 32502443 ↗
  • Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010 Feb;30(1):52-60. doi: 10.1055/s-0030-1247132. Epub 2010 Feb 19. PubMed 20175033 ↗
  • Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5. PubMed 20525992 ↗
  • Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294. PubMed 20818862 ↗
  • Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012 Dec 15;18(24):6580-7. doi: 10.1158/1078-0432.CCR-12-1362. Epub 2012 Oct 19. PubMed 23087408 ↗
  • Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005 Apr;54(4):307-14. doi: 10.1007/s00262-004-0593-x. Epub 2004 Dec 15. PubMed 15599732 ↗
  • Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704. doi: 10.1146/annurev.immunol.26.021607.090331. PubMed 18173375 ↗
  • Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007 Jul;27(1):111-22. doi: 10.1016/j.immuni.2007.05.016. Epub 2007 Jul 12. PubMed 17629517 ↗
  • Yang H, Shi J, Lin D, Li X, Zhao C, Wang Q, Zhang L, Jiang T, Zhao S, Liu X, Jia Y, Zhang Y, Cai W, Zhou C. Prognostic value of PD-L1 expression in combination with CD8+ TILs density in patients with surgically resected non-small cell lung cancer. Cancer Med. 2018 Jan;7(1):32-45. doi: 10.1002/cam4.1243. Epub 2017 Nov 23. PubMed 29168339 ↗
  • Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother. 2007 May;56(5):739-45. doi: 10.1007/s00262-006-0272-1. Epub 2006 Dec 29. PubMed 17195077 ↗
  • Llovet JM, Lencioni R. mRECIST for HCC: Performance and novel refinements. J Hepatol. 2020 Feb;72(2):288-306. doi: 10.1016/j.jhep.2019.09.026. PubMed 31954493 ↗
  • Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Somerfield MR, Falanga A; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015 Feb 20;33(6):654-6. doi: 10.1200/JCO.2014.59.7351. Epub 2015 Jan 20. PubMed 25605844 ↗
  • Orsmond GI, Cohn ES. The Distinctive Features of a Feasibility Study: Objectives and Guiding Questions. OTJR (Thorofare N J). 2015 Jul;35(3):169-77. doi: 10.1177/1539449215578649. PubMed 26594739 ↗
  • Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026. PubMed 19097774 ↗
  • Ravelli A, Minoia F, Davi S, Horne A, Bovis F, Pistorio A, Arico M, Avcin T, Behrens EM, De Benedetti F, Filipovic L, Grom AA, Henter JI, Ilowite NT, Jordan MB, Khubchandani R, Kitoh T, Lehmberg K, Lovell DJ, Miettunen P, Nichols KE, Ozen S, Pachlopnik Schmid J, Ramanan AV, Russo R, Schneider R, Sterba G, Uziel Y, Wallace C, Wouters C, Wulffraat N, Demirkaya E, Brunner HI, Martini A, Ruperto N, Cron RQ; Paediatric Rheumatology International Trials Organisation; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology Collaborative Study Group; Histiocyte Society. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2016 Mar;68(3):566-76. doi: 10.1002/art.39332. Epub 2016 Feb 9. PubMed 26314788 ↗

Individual participant data

Plan to share: No — Please contact the study principal investigator for questions regarding data sharing.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Apr 2027, 51 months after the start.

Of 38 phase 4 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 118. This study's planned 51 months is below that.

Completion moved once since we started tracking on Sep 25, 2026: Oct 2027 → Oct 2028, on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2021
First posted
Jan 11, 2022
StartActual
Jan 30, 2023
Primary completionEst.
Apr 30, 2027
CompletionEst.
Oct 31, 2028was Oct 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Enrolling by invitation
changed Oct 8, 2026
Sites
1 site added — first site in Canada
Show site
  • Toronto General Hospital, University Health Network · Toronto, Canada
Oct 8, 2026
Study completion
Oct 31, 2027→Oct 31, 2028
Oct 8, 2026
Eligibility
12 inclusion criteria edited, 2 added, 1 removed; 12 exclusion criteria edited, 4 added, 2 removed
What changed in the criteria
Inclusion criteria
  • EditedHistologically or radiologically proven HCC, without extrahepatic disease. Patients who consent to a fresh tissue biopsybiospy, and under the discretion of the Investigators, will provide a baseline biopsy sample for diagnosis and correlative studies. Archival tumor tissue may be used to confirm HCC in patients who do not consent to a fresh tissue biopsy.
  • EditedPrior remote LRT is allowed if new lesions or local disease recurrence are present. Participants may have received one TACE or TARE treatment within 8 weeks prior to enrollment, whether or not new lesions are present.
  • ChangedBefore Must be eligible for liver transplantation, defined in Section 10.4Now Must be undergoing evaluation for or waitlisted for liver transplantation
  • EditedEligible and suited to receive TACE or TARE procedure(s)
  • EditedChild-Pugh score ≤A6B7
  • EditedLymphocyte count ≥ 0.5 x 10\^9/L (500/uLμL)
  • EditedPlatelet count > 75 x 10910\^9/L
  • EditedHemoglobin >≥ 9 g/dL
  • EditedSerum creatinine < 1.5x ULN or calculated creatinine clearance < 50 ml/min
  • EditedUrine dipstick for proteinuria ≥≤ 2+ unless a 24-hour urine protein < 1 g of protein is demonstrated
  • RemovedNo evidence of a Grade 2 or higher esophageal and/or gastric varices. Patients must have an esophagogastroduodenoscopy (EGD) within 6 months prior to initiating the study treatment. See Section 8.7.1.2.
  • AddedDocumentation of referral to the Transplant Hepatology team for appropriate evaluation and management of patients who have one or more of the following:
  • EditedNegativePositive hepatitis B surface antigen (HBsAg) test at screening or transplant workup
  • EditedNegativePositive total hepatitis B core antibody (HBcAb) test at screening or transplant workup, or positive total HBcAb test followed by a negativepositive hepatitis B virus (HBV) DNA test at screening or transplant workup. The HBV DNA test willmust be performed only for patients who have a negative HBsAg test and a positive total HBcAb test.
  • AddedPositive hepatitis C virus (HCV) antibody test at screening followed by a positive HCV RNA test at screening. The HCV RNA test must be performed for patients who have a positive HCV antibody test.
Exclusion criteria
  • AddedEvidence of a Grade 2 or higher esophageal and/or gastric varices. Patients must have an esophagogastroduodenoscopy (EGD) within 6 months prior to initiating the study treatment. See Section 8.7.1.2. If the EGD shows Grade 2 or higher esophageal and/or gastric varices, patients will be excluded and will not receive study treatment but can be re-evaluated for enrollment after successful treatment of varices according to institutional guidelines.
  • EditedSignificant vascular disease (e.g.eg, aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to drug administration
  • ChangedBefore Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable anginaNow Clinically significant cardiovascular disease, such as cerebrovascular accidents within 12 months prior to randomization, myocardial infarction within 12 months prior to randomization, unstable angina, New York Heart Association (NYHA) Grade II or greater CHF, or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with study treatment
  • EditedHistory or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e.ie, in the absence of therapeutic anticoagulation)
  • EditedSurgicalMajor surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to initiation of study treatment, or anticipation of need for major surgical procedure during the Treatment Phase of the study
  • RemovedCore biopsy or other minor surgical procedure, excluding placement of a vascular access device within 7 days prior to initiation of study treatment. Placement of a vascular access device should be at least 2 days prior to initiation of study treatment.
  • AddedTreatment should not be initiated within 7 days of having a core biopsy or other minor surgical procedure.
  • AddedTreatment should not be initiated within 2 days of placement of a vascular access device.
  • RemovedUntreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk for bleeding. Patients must undergo an esophagogastroduodenoscopy (EGD), and all size of varices (small to large) must be assessed and treated per local standard of care prior to enrollment. Patients who have undergone an EGD within 6 months prior to initiating the study treatment do not need to repeat the procedure.
  • EditedCurrent or recent (<10 days prior to initiation of study treatment) use of aspirin (>325 mg/day), or clopidogrel (>75 mg/day). Note: The use of full-dose oral or parenteral anticoagulants for therapeutic purpose is permitted as long as the INR and/or a PTT is within therapeutic limits (according to institution standards) within 147 days prior to initiation of study treatment and the patient has been on a stable dose of anticoagulants for ≥2 weeks prior to initiation of study treatment. Prophylactic use of anticoagulants is allowed. However, the use of direct oral anticoagulant therapies such as apixaban (Eliquis®), dabigatran (Pradaxa®), and rivaroxaban (Xarelto®) is not recommended due to bleeding risk, unless approved by the treating physician and the primary investigator.
  • Editedo Women of childbearing potential must have a negative serum or urine pregnancy test result within 28 days prior to initiation of study treatment.
  • EditedPatients with indwelling catheters (e.g.eg, PleurX®) are allowed
  • AddedPatients with controlled Type 1 Diabetes Mellitus who are on an insulin regimen are eligible for the study
  • EditedTreatment with a live, attenuated vaccine (e.g.eg, FluMist®) within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab
  • ChangedBefore Current treatment with anti-viral therapy for HBVNow Treatment with investigational therapy within 28 days prior to initiation of study treatment
  • EditedPatients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g.eg, 48 hours of corticosteroids for a contrast allergy) are eligible for the study after Principal Investigator confirmation has been obtained.
  • EditedPatients receiving prophylactic antibiotics (e.g.eg, to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.
  • EditedHistory of intra-abdominal inflammatory process within 6 months prior to initiation of study treatment, including but not limited to active peptic ulcer disease, diverticulititsdiverticulitis, or colitis.
Oct 8, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionProportion of Patients Receiving Liver Transplant Experiencing Acute Rejection: how it is measured was reworded
Oct 8, 2026
Secondary outcomes
1 added, 1 description edited
What changed in the outcomes
  • AddedOverall Survival after Study EnrollmentTime frame: Through study completion, up to 4 years
  • DescriptionObjective Response Rate: how it is measured was reworded
Oct 8, 2026
Contact
No study contact listed any more: removed d•••@houstonmethodist.org · •••6232; removed s•••@houstonmethodist.org · •••5122
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Recruiting→Enrolling by invitation
    1 site added — first site in Canada
    Show site
    • Toronto General Hospital, University Health Network · Toronto, Canada
    Study completion Oct 31, 2027→Oct 31, 2028
    Eligibility 12 inclusion criteria edited, 2 added, 1 removed; 12 exclusion criteria edited, 4 added, 2 removed
    What changed in the criteria
    Inclusion criteria
    • EditedHistologically or radiologically proven HCC, without extrahepatic disease. Patients who consent to a fresh tissue biopsybiospy, and under the discretion of the Investigators, will provide a baseline biopsy sample for diagnosis and correlative studies. Archival tumor tissue may be used to confirm HCC in patients who do not consent to a fresh tissue biopsy.
    • EditedPrior remote LRT is allowed if new lesions or local disease recurrence are present. Participants may have received one TACE or TARE treatment within 8 weeks prior to enrollment, whether or not new lesions are present.
    • ChangedBefore Must be eligible for liver transplantation, defined in Section 10.4Now Must be undergoing evaluation for or waitlisted for liver transplantation
    • EditedEligible and suited to receive TACE or TARE procedure(s)
    • EditedChild-Pugh score ≤A6B7
    • EditedLymphocyte count ≥ 0.5 x 10\^9/L (500/uLμL)
    • EditedPlatelet count > 75 x 10910\^9/L
    • EditedHemoglobin >≥ 9 g/dL
    • EditedSerum creatinine < 1.5x ULN or calculated creatinine clearance < 50 ml/min
    • EditedUrine dipstick for proteinuria ≥≤ 2+ unless a 24-hour urine protein < 1 g of protein is demonstrated
    • RemovedNo evidence of a Grade 2 or higher esophageal and/or gastric varices. Patients must have an esophagogastroduodenoscopy (EGD) within 6 months prior to initiating the study treatment. See Section 8.7.1.2.
    • AddedDocumentation of referral to the Transplant Hepatology team for appropriate evaluation and management of patients who have one or more of the following:
    • EditedNegativePositive hepatitis B surface antigen (HBsAg) test at screening or transplant workup
    • EditedNegativePositive total hepatitis B core antibody (HBcAb) test at screening or transplant workup, or positive total HBcAb test followed by a negativepositive hepatitis B virus (HBV) DNA test at screening or transplant workup. The HBV DNA test willmust be performed only for patients who have a negative HBsAg test and a positive total HBcAb test.
    • AddedPositive hepatitis C virus (HCV) antibody test at screening followed by a positive HCV RNA test at screening. The HCV RNA test must be performed for patients who have a positive HCV antibody test.
    Exclusion criteria
    • AddedEvidence of a Grade 2 or higher esophageal and/or gastric varices. Patients must have an esophagogastroduodenoscopy (EGD) within 6 months prior to initiating the study treatment. See Section 8.7.1.2. If the EGD shows Grade 2 or higher esophageal and/or gastric varices, patients will be excluded and will not receive study treatment but can be re-evaluated for enrollment after successful treatment of varices according to institutional guidelines.
    • EditedSignificant vascular disease (e.g.eg, aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to drug administration
    • ChangedBefore Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable anginaNow Clinically significant cardiovascular disease, such as cerebrovascular accidents within 12 months prior to randomization, myocardial infarction within 12 months prior to randomization, unstable angina, New York Heart Association (NYHA) Grade II or greater CHF, or serious cardiac arrhythmia uncontrolled by medication or potentially interfering with study treatment
    • EditedHistory or evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e.ie, in the absence of therapeutic anticoagulation)
    • EditedSurgicalMajor surgical procedure (including open biopsy, surgical resection, wound revision, or any other major surgery involving entry into a body cavity) or significant traumatic injury within 28 days prior to initiation of study treatment, or anticipation of need for major surgical procedure during the Treatment Phase of the study
    • RemovedCore biopsy or other minor surgical procedure, excluding placement of a vascular access device within 7 days prior to initiation of study treatment. Placement of a vascular access device should be at least 2 days prior to initiation of study treatment.
    • AddedTreatment should not be initiated within 7 days of having a core biopsy or other minor surgical procedure.
    • AddedTreatment should not be initiated within 2 days of placement of a vascular access device.
    • RemovedUntreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk for bleeding. Patients must undergo an esophagogastroduodenoscopy (EGD), and all size of varices (small to large) must be assessed and treated per local standard of care prior to enrollment. Patients who have undergone an EGD within 6 months prior to initiating the study treatment do not need to repeat the procedure.
    • EditedCurrent or recent (<10 days prior to initiation of study treatment) use of aspirin (>325 mg/day), or clopidogrel (>75 mg/day). Note: The use of full-dose oral or parenteral anticoagulants for therapeutic purpose is permitted as long as the INR and/or a PTT is within therapeutic limits (according to institution standards) within 147 days prior to initiation of study treatment and the patient has been on a stable dose of anticoagulants for ≥2 weeks prior to initiation of study treatment. Prophylactic use of anticoagulants is allowed. However, the use of direct oral anticoagulant therapies such as apixaban (Eliquis®), dabigatran (Pradaxa®), and rivaroxaban (Xarelto®) is not recommended due to bleeding risk, unless approved by the treating physician and the primary investigator.
    • Editedo Women of childbearing potential must have a negative serum or urine pregnancy test result within 28 days prior to initiation of study treatment.
    • EditedPatients with indwelling catheters (e.g.eg, PleurX®) are allowed
    • AddedPatients with controlled Type 1 Diabetes Mellitus who are on an insulin regimen are eligible for the study
    • EditedTreatment with a live, attenuated vaccine (e.g.eg, FluMist®) within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the final dose of atezolizumab
    • ChangedBefore Current treatment with anti-viral therapy for HBVNow Treatment with investigational therapy within 28 days prior to initiation of study treatment
    • EditedPatients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g.eg, 48 hours of corticosteroids for a contrast allergy) are eligible for the study after Principal Investigator confirmation has been obtained.
    • EditedPatients receiving prophylactic antibiotics (e.g.eg, to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.
    • EditedHistory of intra-abdominal inflammatory process within 6 months prior to initiation of study treatment, including but not limited to active peptic ulcer disease, diverticulititsdiverticulitis, or colitis.
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionProportion of Patients Receiving Liver Transplant Experiencing Acute Rejection: how it is measured was reworded
    Secondary outcomes 1 added, 1 description edited
    What changed in the outcomes
    • AddedOverall Survival after Study EnrollmentTime frame: Through study completion, up to 4 years
    • DescriptionObjective Response Rate: how it is measured was reworded
    Contact No study contact listed any more: removed d•••@houstonmethodist.org · •••6232; removed s•••@houstonmethodist.org · •••5122
    + 6 other changes: index terms, verification date, description, arm descriptions, references and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05185505
Collaborators
Genentech, Inc.
Responsible party
Maen Abdelrahim, MD, PhD, Pharm.B (Associate Professor of Medicine in Oncology, Houston Methodist Academic Institute, The Methodist Hospital Research Institute) — Principal investigator
First posted
Jan 11, 2022
Start date
Jan 30, 2023
Primary completion
Apr 30, 2027 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Oct 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atezolizumab · Bevacizumab

Start the discussion